文献速递泌尿生殖与妇科肿瘤放疗

多西他赛联合ADT治疗高危前列腺癌的III期试验

Phase 3 Trial of Dose-Escalated Radiation Therapy and Standard Androgen Deprivation Therapy Versus Dose-Escalated Radiation Therapy and Enhanced Androgen Deprivation Therapy With Orteronel for Men With High-Risk Prostate Cancer (NRG/RTOG 1115).
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2025-07-23

NRG/RTOG 1115是一项III期试验,评估在高危前列腺癌男性中,在放疗(RT)联合雄激素剥夺治疗(ADT)的基础上加用orteronel(一种CYP17A1抑制剂)的疗效。研究设计纳入900例高危前列腺癌患者,随机接受标准治疗(RT+2年ADT)或标准治疗+2年orteronel。由于orteronel开发终止, accrual提前停止,仅231例合格患者入组,结果显示加用orteronel未显著改善总生存或生化失败,但≥3级不良事件发生率更高。

要点

  • orteronel对前列腺癌特异性生活质量领域有短暂负面影响,但未增加放疗开始后的下降幅度,对其他健康相关生活质量影响极小。

核心结论

  • 在高危前列腺癌患者中,在放疗和ADT基础上加用orteronel未显著改善任何疗效结局。
  • 研究信息受药物耐受性差和 accrual提前终止的限制,统计效力有限。

研究设计与样本

  • III期随机试验,计划纳入900例高危前列腺癌男性(Gleason 9-10、PSA>20或临床分期T2及以上且Gleason≥8),随机1:1接受标准治疗(放疗+2年ADT)或标准治疗+2年orteronel。
  • 放疗包括图像引导常规分割剂量递增外照射至前列腺和盆腔45 Gy,使用调强放疗,随后调强放疗推量至79.2 Gy或近距离放疗推量。
  • 由于orteronel开发终止, accrual提前停止,试验重新设计以复合生化失败终点为重点;共231例合格随机患者。

主要发现

  • orteronel组仅29%接受≥80%计划剂量。
  • orteronel对EPIC所有前列腺癌特异性生活质量领域有短暂负面影响,但未增加放疗开始后的下降幅度,对其他健康相关生活质量指标影响极小。

临床怎么用

  • 不推荐在高危前列腺癌的放疗和ADT基础上常规加用orteronel,因未显示疗效改善且毒性增加。
  • 临床决策时应考虑药物耐受性和研究统计效力有限。

局限性

  • accrual提前终止和药物耐受性差导致统计效力有限。
  • orteronel组仅29%接受≥80%计划剂量,可能影响疗效评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: NRG/RTOG 1115 was a phase 3 trial evaluating the addition of orteronel, a CYP17A1 inhibitor, to radiation therapy (RT) plus androgen deprivation therapy (ADT) in men with high-risk prostate cancer. METHODS AND MATERIALS: The study was designed to evaluate overall survival for 900 men with high-risk prostate cancer (Gleason 9-10, prostate specific antigen (PSA) > 20, or clinical stage T2 or higher with Gleason ≥ 8). Patients were randomized 1:1 to standard of care (SOC) therapy (RT plus 2 years of ADT) or SOC plus 2 years of orteronel. RT entailed image guided conventionally fractionated dose-escalated external beam RT to the prostate and pelvis to 45 Gy using intensity modulated RT with either intensity modulated RT (to 79.2 Gy) or brachytherapy boost. Health-related quality of life (HRQOL) was measured using the Expanded Prostate cancer Index Composite (EPIC), Patient-Reported Outcome Measurement Information System (PROMIS) fatigue, and EQ-5D. Accrual was halted early because of discontinuation of orteronel development and the trial redesigned to focus on a composite biochemical failure endpoint. RESULTS: There were a total of 231 eligible randomized patients. Only 29% in the orteronel arm received ≥80% of the planned dose. With median follow-up of 6.2 years, the cumulative incidence of grade 3+ adverse events was higher on orteronel than on the standard arm (P < .001; hazard ratio [HR], 2.32; 95% CI, 1.52-3.47) with 5-year estimates of 59.0% and 35.1%, respectively. No significant differences in overall survival (P = .28; HR, 0.71; 95% CI, 0.39-1.32) or biochemical failure (P = .56; HR, 0.84; 95% CI, 0.47-1.51) were observed. Use of orteronel had a transient negative impact on all prostate cancer-specific QOL domains of the EPIC, but did not increase the magnitude of decline once RT started and had minimal impact on other HRQOL measures. CONCLUSIONS: The addition of orteronel to RT and ADT did not result in significant improvement in any efficacy outcomes, although information was limited by poor drug tolerance and early termination of accrual, thus limiting statistical power.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Hamstra DA, Dignam JJ, Bruner DW, et al. Phase 3 Trial of Dose-Escalated Radiation Therapy and Standard Androgen Deprivation Therapy Versus Dose-Escalated Radiation Therapy and Enhanced Androgen Deprivation Therapy With Orteronel for Men With High-Risk Prostate Cancer (NRG/RTOG 1115). Int J Radiat Oncol Biol Phys. 2025. PMID: 40712984. doi:10.1016/j.ijrobp.2025.07.1425

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。